Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGN-35T
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SGN-35T is an investigational antibody-drug conjugate (ADC) designed to target CD30-expressing cancer cells. It consists of an anti-CD30 monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a novel protease-cleavable tripeptide linker, with a drug-to-antibody ratio of approximately four. The mechanism of action involves binding to CD30 on tumor cells, internalization, and intracellular release of MMAE, which disrupts microtubule function and induces cell death. SGN-35T is being developed primarily for the treatment of relapsed or refractory Hodgkin lymphoma and various types of non-Hodgkin lymphoma[1][4][5].
02
Targets
CD30 (CD30 antigen)
Beyond the preview
Go deeper on SGN-35T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGN-35T.